{"id":9521,"date":"2025-07-14T16:49:05","date_gmt":"2025-07-14T16:49:05","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/9521\/"},"modified":"2025-07-14T16:49:05","modified_gmt":"2025-07-14T16:49:05","slug":"u-s-next-generation-sequencing-library-preparation-market-size-to-surpass-usd-2237-13-million-by-2034","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/9521\/","title":{"rendered":"U.S. Next-generation Sequencing Library Preparation Market Size to Surpass USD 2,237.13 Million by 2034"},"content":{"rendered":"

<\/p>\n

The U.S.
\nnext-generation sequencing library preparation market size<\/a> is
\ncalculated at USD 652.65 million in 2024, grows to USD 738.21 million in 2025,
\nand is projected to reach around USD 2,237.13 million by 2034, growing at a
\nCAGR of 13.11% from 2025 to 2034.<\/p>\n

<\/p>\n

The U.S. next-generation sequencing library
\npreparation market is growing due to its many benefits, as these solutions save
\ntime and money, and they are improved specifically for instruments and
\nsecondary analysis platforms. Even those consumers who are new to NGS find that
\nthe workflows and applications are simple to adopt.<\/p>\n

The Complete Study is Now Available for
\nImmediate Access | Download the Sample Pages of this Report@ https:\/\/www.novaoneadvisor.com\/report\/sample\/9174<\/a>\n<\/p>\n

U.S. Next-generation Sequencing Library
\nPreparation Market Highlights:<\/p>\n

\u2022 \u00a0By sequencing type, the targeted genome
\nsequencing segment dominated the market with the largest share in 2024.<\/p>\n

\u2022 \u00a0By sequencing type, the whole genome
\nsequencing segment is expected to show the fastest growth over the forecast
\nperiod.<\/p>\n

\u2022 \u00a0By product, the reagents and consumables
\nsegment held the largest market share in 2024.<\/p>\n

\u2022 \u00a0By product, the instruments segment is
\nexpected to register the fastest growth during the forecast period.<\/p>\n

\u2022 \u00a0By application, the drug & biomarker
\ndiscovery segment captured the largest market share in 2024.<\/p>\n

\u2022 \u00a0By application, the disease diagnostics
\nsegment is expected to show the fastest growth during the forecast period.<\/p>\n

\u2022 \u00a0By end use, the academic & research
\ninstitutions segment generated the highest market revenue in 2024. <\/p>\n

\u2022 \u00a0By end use, the pharmaceutical and biotechnology
\ncompanies\u2019 segment is expected to register the fastest CAGR during the
\npredicted timeframe.<\/p>\n

Market Overview and Industry Potential<\/p>\n

The U.S. next-generation sequencing library
\npreparation market is expanding rapidly due to the library preparation techniques
\ninvolve converting a genomic
\nDNA<\/a> sample into a library of fragments. It is an affordable and
\ntime-saving procedure. Continue advancement in NGS library preparation with
\nadvanced technology a resulting a bit becoming easier to use, scalable for any
\nsize lab, requiring a small number of steps, and having a rapid workflow time. <\/p>\n

It provides many benefits, such as proper
\nlibrary preparation, reducing biases, ensuring even coverage, and lowering
\nerrors, leading to high-quality sequencing data. Libraries applied for
\nparticular applications, like whole-genome sequencing, transcriptome analysis,
\nexome sequencing, metagenomics<\/a>,
\nor epigenomics. Augmented protocols save time and resources, allowing
\nhigh-throughput sequencing projects. Specific protocols enable the use of
\nrestricted or degraded samples, like formalin-fixed paraffin-embedded (FFPE)
\ntissues.<\/p>\n

\u2022 For Instance, In June 2025, DPX
\nTechnologies, a biotechnology company providing solutions for automated sample
\npreparation, announces its latest products and fully automated workflows
\nutilizing functionalized pipette tips. The products, MicroPorous Xtraction
\n(MPX) Tips and NiXTips, are designed for DNA extraction and nucleic acid
\ncleanup.<\/p>\n

What are Major Steps of NGS Library
\nPreparation?<\/p>\n

NGS library preparation has four usual
\nsteps, such as DNA
\nfragmentation<\/a> or selection of target, adapter sequences addition, size
\nselection, and lastly, library quantification and QC. It involves converting
\nnucleic acid samples (gDNA or cDNA) into a library of homogeneously sized,
\nadapter-ligated DNA fragments, which are then sequenced using an NGS
\ninstrument.<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/9174<\/a>\n<\/p>\n

Advantages of Next-generation Sequencing
\nLibrary Preparation Market<\/p>\n

Application<\/p>\n

Advantages<\/p>\n

DNA\/RNA Requirement<\/p>\n

Low DNA\/RNA input<\/p>\n

Single investment for screening multiple samples<\/p>\n

Multiple Marker & Variant Types<\/p>\n

Screening of multiple genes<\/p>\n

Multiple variant types<\/p>\n

Detection of heterogeneity<\/p>\n

\u00a0<\/p>\n

High throughput<\/p>\n

Screening of multiple samples<\/p>\n

High Sensitivity<\/p>\n

High sensitivity Sanger\/PYRO sequencing<\/p>\n

Reporting<\/p>\n

Single clinical report with mutation states of multiple markers<\/p>\n

\u00a0<\/p>\n

What are Latest Trends in
\nNest-generation Sequencing Library Preparation Market?<\/p>\n

\u2022 In October 2024, Illumina, Inc., a global
\nleader in DNA
\nsequencing<\/a> and array-based technologies, unveiled its MiSeq i100 Series
\nof sequencing systems, delivering unparalleled benchtop speed and simplicity to
\nadvance next-generation sequencing (NGS) for labs.<\/p>\n

\u2022 In January 2024, QIAGEN Digital Insights
\n(QDI), the bioinformatics business of QIAGEN, announced its enhanced QIAGEN CLC
\nGenomics Workbench Premium with LightSpeed technology now supports
\nnext-generation sequencing (NGS) for somatic cancer secondary analysis. <\/p>\n

\u2022 In August 2024, Illumina, Inc. announced
\nFood and Drug Administration (FDA) approval of its in vitro diagnostic (IVD)
\nTru Sight Oncology (TSO) Comprehensive test and its first two companion
\ndiagnostic (CDx) indications. This single test interrogates over 500 genes to
\nprofile a patient’s solid tumor, helping to increase the likelihood of
\nidentifying an immuno-oncology biomarker or clinically actionable biomarkers
\nthat enable targeted therapy options or clinical trial enrollment.<\/p>\n

Increasing Digitalization in CDMO:
\nMarket\u2019s Largest Potential<\/p>\n

Next-generation
\nsequencing<\/a> (NGS) library preparation is a significant tool used in
\ngenomics research. NGS sequences millions of DNA fragments at the same time,
\noffering detailed information related to the structure of genomes, gene
\nactivity, genetic variations, and fluctuations in gene behaviour. Modern
\ndevelopments focused on rapid and more precise sequencing, lower expenses, and
\nbetter data analysis. These advancements hold great promise for unlocking novel
\nopportunities in genomics and enhancing the understanding of diseases and
\npersonalized healthcare. This revolutionary technology has driven genomics advancements
\nin the various domains of healthcare.<\/p>\n

\u2022 For Instance, In June 2025, Illumina,
\nInc. announced it has entered into a definitive agreement with Standard
\nBioTools under which Illumina will acquire SomaLogic, a leader in data-driven
\nproteomics technology, and other specified assets for $350 million in cash
\npayable at closing, subject to customary adjustments, plus up to $75 million in
\nnear-term performance-based milestones and performance-based royalties.<\/p>\n

U.S. Next-generation Sequencing Library
\nPreparation Market: What to Expect in the Country in Upcoming Period?<\/p>\n

In the U.S. increasing application of
\nnext-generation sequencing is due to its ability to transform all fields of
\nbiological science. Increasing application of precision medicines has allowed
\nclinicians to gain a better understanding of novel rare genetic diseases
\nbecause of the use of next-generation
\nsequencing<\/a> (NGS) technologies. <\/p>\n

Also in this region, advancements in
\ngenetic testing, growing prevalence of chronic diseases, and an increasing
\nimportance of patient-centered care increase the demand for next-generation
\nsequencing library preparation.<\/p>\n

\u2022 For Instance, In April 2025, Watchmaker
\nGenomics announced an important milestone in providing comprehensive and robust
\nautomated solutions for next-generation sequencing (NGS) workflows. Its
\ncollaboration with Revvity has resulted in fully automated and verified methods
\nfor all of its DNA and RNA library preparation kits on the Sciclone G3 NGSx
\nliquid handling workstation, making Revvity the first provider to automate
\nWatchmaker\u2019s entire library preparation portfolio.\u00a0\u00a0\u00a0 <\/p>\n

Report Scope of U.S. Next-generation
\nSequencing Library Preparation Market<\/p>\n

Report Coverage<\/p>\n

Details<\/p>\n

Market Size in 2025<\/p>\n

USD 738.21 Million<\/p>\n

Market Size by 2034<\/p>\n

USD 2,237.13 Million<\/p>\n

Growth Rate From 2025
\n to 2034<\/p>\n

CAGR of 13.11%<\/p>\n

Base Year<\/p>\n

2024<\/p>\n

Forecast Period<\/p>\n

2025-2034<\/p>\n

Segments Covered<\/p>\n

Product, Sequencing
\n Type, Application, and End use<\/p>\n

Market Analysis
\n (Terms Used)<\/p>\n

Value (US$
\n Million\/Billion) or (Volume\/Units)<\/p>\n

Key Companies
\n Profiled<\/p>\n

Agilent Technologies,
\n Inc., BD, F. Hoffmann-La Roche AG, Inc., Illumina, Inc., New England Biolabs
\n Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc.,
\n QIAGEN N.V., Revvity, Inc., Thermo Fisher Scientific Inc.<\/p>\n

\u00a0<\/p>\n

U.S. Next-generation Sequencing Library
\nPreparation Market Segmentation Analysis:<\/p>\n

By Sequencing Type Analysis:<\/p>\n

The targeted genome sequencing segment
\ndominates in the U.S. next-generation sequencing library preparation market, as
\nit focuses on a particular genomic region of interest. This technology is best
\nfor investigating genes in precise pathways or for follow-up experiments as
\ncompared to whole-genome sequencing (WGS). It is fast and more affordable than
\nWGS, and it allows for deeper sequencing. Targeted sequencing is an extremely
\nsensitive and significant technique for recognizing variants and mutations,
\nincluding rare variants. <\/p>\n

On the other hand, the whole genome
\nsequencing segment is expected to grow significantly during the forecast period
\nas it is the most inclusive genomic test available. It is used to test a broad
\nrange of genes simultaneously, identifying a range of variant types.\u00a0 WGS has
\nhuge potential to identify variants in both protein-coding regions and
\nnon-coding, possibly intended regions. <\/p>\n

By Product Analysis:<\/p>\n

The reagents and consumables segment
\ndominates the U.S. Next-generation sequencing library preparation market, as
\nNGS Reagents are complete sets of optimized reagents that are perfect to
\nconvert a small quantity of DNA \/ RNA input into indexed libraries. NGS allows
\nthe best throughput per run, and studies are performed rapidly and affordable
\ncost. NGS needs lower sample input, it provides higher accuracy, and the
\nability to identify variants at lower allele frequencies as compared to Sanger
\nsequencing<\/p>\n

The instruments segment is expected to grow
\nsignificantly during the forecast period, as the instruments provide the main
\nadvantages over traditional sequencing approaches, primarily because of their
\nhigh throughput, speed, and scalability. NGS instrument allows for the same
\ntime sequencing of millions of DNA fragments, offering comprehensive genomic
\ninsights, rapid turnaround times, and lower costs compared to traditional
\ntechnologies. <\/p>\n

By Drug & Biomarker Discovery
\nAnalysis:<\/p>\n

The drug & biomarker discovery segment
\ncaptured the largest market share in 2024, as NGS supports investigators to
\ndiscover novel therapeutics, combat drug resistance, and prevent disease
\nevolution. NGS enables the identification of gene mutations and the determination
\nof disease progression via biomarker prediction and genetically stratified
\nclinical trials. It brings numerous advantages to biomarker discovery,
\nincluding the ability to perform deep sequencing, which allows the detection of
\nlow-frequency genetic variants, and enormously parallel sequencing.<\/p>\n

The disease diagnostics segment is expected
\nto show the fastest growth during the forecast period, as NGS is used in the
\ndiagnosis of various diseases. As microbes grown from patient samples offer
\nmicrobial DNA for WGS, in which millions of fragments are read in parallel and
\nassembled to rebuild the microbial genome. NGS has the potential to speed up
\nthe detection of disorders and create personalised pharmacogenomics profiles
\nfor different types of diseases.<\/p>\n

By End Use Analysis:<\/p>\n

The academic & research institutions
\nsegment generated the highest market revenue in 2024, as next-generation
\nsequencing (NGS) is a novel technology used for DNA and RNA sequencing and
\nvariant\/mutation detection in healthcare research. NGS sequences hundreds or
\nthousands of genes or a whole genome in a limited period. Next-generation
\nsequencing (NGS) is a significant tool used in genomics research.<\/p>\n

\"A<\/p>\n

The pharmaceutical and biotechnology
\ncompanies\u2019 segment is expected to register the fastest CAGR during the
\npredicted timeframe as NGS technologies are used to appearance for microbial
\ncontaminants to offer precise surveillance of the drug manufacturing solution.
\nIn the pharmaceutical and biotechnology industry, it drives large knowledge-gaining
\nexperiments that could not be financially defensible or were not even possible
\nin the past, including metagenomics to compare various disease states or
\npatient inconsistency, genome sequencing of model organisms, or ELT compound
\nlibrary screening procedures.<\/p>\n

Some of the Prominent Players in the
\nU.S. Next-generation Sequencing Library Preparation Market<\/p>\n

\u2022 Agilent
\nTechnologies, Inc<\/a>.<\/p>\n

\u2022 BD<\/a><\/p>\n

\u2022 F. Hoffmann-La Roche AG, Inc.<\/p>\n

\u2022 Illumina,
\nInc<\/a>.<\/p>\n

\u2022 New England Biolabs Inc.<\/p>\n

\u2022 Oxford Nanopore Technologies<\/p>\n

\u2022 Pacific Biosciences of California, Inc.<\/p>\n

\u2022 QIAGEN N.V.<\/p>\n

\u2022 Revvity,
\nInc.<\/a><\/p>\n

\u2022 Thermo Fisher Scientific Inc.<\/p>\n

What is Going Around the Globe?<\/p>\n

\u2022 In February 2025, Roche unveiled its
\nproprietary, breakthrough sequencing by expansion (SBX) technology,
\nestablishing a new category of next-generation sequencing. SBX chemistry,
\ncombined with an innovative sensor module, offers ultra-rapid, high-throughput
\nsequencing that is both flexible and scalable for a broad range of
\napplications. <\/p>\n

\u2022 In May 2025, Illumina, Inc., and
\nOvation.io, Inc., an organization dedicated to building best-in-class
\nmultiomics datasets, announced the development of the largest commercially
\navailable clinical multiomic dataset from 25,000 patients treated with
\nglucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be
\nmade available to the pharma community to advance drug discovery and
\ndevelopment. <\/p>\n

\u2022 In June 2024, the Life Science division
\nof Meridian Bioscience, Inc., a leading global provider of diagnostic testing
\nsolutions and life science raw materials, proudly introduces the market\u2019s first
\ninnovative lyophilized Next-Generation Sequencing (NGS) library preparation
\nkit. This pioneering kit underscores Meridian\u2019s commitment to sustainable and
\ncost-effective solutions within the life sciences industry.\u00a0\u00a0 <\/p>\n

\u2022 In April 2025, Zymo Research Corp
\nannounced the launch of its revolutionary new technology: The Green DNA\/RNA Dry
\nTransport System. This new tool sets the standard for eco-conscious,
\ncost-effective, and room temperature transportation of DNA and RNA samples and
\nis ideal for prepared libraries for any commercial sequencing platform.<\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact at\u00a0sales@novaoneadvisor.com<\/a> \u00a0|
\n+1 804 441 9344<\/p>\n

Segments Covered in the Report<\/p>\n

This report forecasts revenue growth at
\ncountry levels and provides an analysis of the latest industry trends in each
\nof the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
\nhas segmented the U.S. Next-generation Sequencing Library Preparation Market.<\/p>\n

By Sequencing Type<\/p>\n

\u2022 Targeted Genome Sequencing<\/p>\n

\u2022 Whole Genome Sequencing<\/p>\n

\u2022 Whole Exome Sequencing<\/p>\n

\u2022 Other Sequencing Types<\/p>\n

By Product<\/p>\n

\u2022 Reagents & Consumables<\/p>\n

\u1d52 DNA Library Preparation Kits<\/p>\n

\u1d52 RNA Library Preparation Kits<\/p>\n

\u1d52 Other Reagents & Consumables<\/p>\n

\u2022 Instruments<\/p>\n

By Application<\/p>\n

\u2022 Drug & Biomarker Discovery<\/p>\n

\u2022 Disease Diagnostics<\/p>\n

\u1d52 Cancer Diagnostics<\/p>\n

\u1d52 Reproductive Health Diagnostics<\/p>\n

\u1d52 Infectious Disease Diagnostics<\/p>\n

\u1d52 Other Disease Diagnostic
\nApplications<\/p>\n

\u1d52 Others<\/p>\n

By End Use<\/p>\n

\u2022 Hospitals and Clinics<\/p>\n

\u2022 Academic and Research Institutions<\/p>\n

\u2022 Pharmaceutical and Biotechnology
\nCompanies<\/p>\n

\u2022 Others<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/9174<\/a>\n<\/p>\n

About-Us<\/p>\n

Nova One Advisor is a global leader
\nin market intelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire
\nbiotech and pharmaceutical value chain, empowering startups, global
\nenterprises, investors, and research institutions that are pioneering the next
\ngeneration of therapies in regenerative medicine, oncology, and precision
\nmedicine. <\/p>\n

Web: https:\/\/www.novaoneadvisor.com\/<\/a><\/p>\n

Contact Us<\/p>\n

USA:\u00a0+1 804 420 9370<\/p>\n

Email: sales@novaoneadvisor.com<\/a><\/p>\n

For Latest Update
\nFollow Us: LinkedIn<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The U.S. next-generation sequencing library preparation market size is calculated at USD 652.65 million in 2024, grows to…\n","protected":false},"author":2,"featured_media":9522,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,79],"class_list":["post-9521","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/9521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=9521"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/9521\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/9522"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=9521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=9521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=9521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}